Arrowhead Pharmaceuticals, Inc. (ARWR) vs Vaxcyte, Inc. (PCVX)

Arrowhead Pharmaceuticals, Inc. and Vaxcyte, Inc. are both Biotechnology companies. Arrowhead Pharmaceuticals, Inc. is the larger, with a market value of $9.3B against $8.5B — 1.1× the size. Vaxcyte, Inc. has the higher net margin (0.00% vs −47.8%) and the lower return on invested capital (−57.3% vs 0.00%). Across the 14 metrics below, Arrowhead Pharmaceuticals, Inc. leads on 8 and Vaxcyte, Inc. on 6.

Valuation

Metric ARWR PCVX Biotechnology median
P/E n/m n/m 7.88
P/S 14.12 n/m 11.47
P/B 20.28 2.95 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 13.02 n/m 10.73
Earnings yield (3.41%) (13.57%) (28.84%)
Free cash flow yield (0.79%) (11.01%) (23.03%)

Profitability

Metric ARWR PCVX Biotechnology median
Gross margin 100.00% 0.00% 65.16%
Operating margin (33.82%) 0.00% 0.00%
Net margin (47.79%) 0.00% 0.00%
Free cash flow margin (11.22%) 0.00% 0.00%
Return on equity (64.91%) (36.51%) (57.72%)
Return on assets (18.32%) (33.03%) (49.22%)
Return on invested capital 0.00% (57.30%) 0.00%

Growth

Metric ARWR PCVX Biotechnology median
Revenue growth (TTM) 16.13% — 5.64%
EPS growth (last fiscal year) 99.80% (48.16%) —
Revenue growth, 5-year CAGR 56.63% — 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ARWR PCVX Biotechnology median
Debt to equity 1.85 0.00 0.00
Current ratio 5.90 5.72 4.73
Net debt to EBITDA (5.70) 1.71 0.96

Dividend

Metric ARWR PCVX Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric ARWR PCVX Biotechnology median
Market cap 9.33b 8.47b 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack